On Friday, Novo Nordisk A/S NVO launched headline outcomes from the REDEFINE 1 Part 3 trial within the world REDEFINE program.
When evaluating the consequences of therapy if all individuals adhered to therapy, individuals handled with CagriSema achieved a weight lack of 22.7% after 68 weeks in comparison with a discount of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and a couple of.3% with placebo alone.
In November, Novo Nordisk stated its hybrid drug, CagriSema, goals to cut back weight by 25% with out added uncomfortable side effects.
William Blair factors out that Novo Nordisk didn’t present detailed tolerability knowledge in its press launch, making it exhausting to check their therapy with Eli Lilly’s Zepbound instantly. Nonetheless, solely 57% of sufferers may enhance their dose to the very best stage with CagriSema, in comparison with 83% with cagrilintide and 70% with Wegovy, suggesting that CagriSema might have a harder tolerability profile.
The analyst writes the tolerability challenge is a key motive why buyers are involved concerning the REDEFINE 1 trial. The analyst charges the shares Outperform.
The outcomes from CagriSema are additionally helpful for Amgen Inc AMGN, which not too long ago confirmed that its GLP-1R agonist/GIPR antagonist, MariTide, results in efficient weight reduction in Part 2 trials.
MariTide’s weight lack of about 20% after 52 weeks (or 18% on the 420 mg dose) is just like or barely under the load loss seen with different GLP-1 therapies, similar to CagriSema and Zepbound.
Additionally Learn: Amgen Defends Its Investigational Month-to-month Weight Loss Injection After Analyst Cites MariTide’s Impression on Bone Density
The analyst writes that MariTide’s benefit may lie in its much less frequent month-to-month dosing, which can stand out within the weight problems market.
Moreover, the best way MariTide is dosed seems to cut back gastrointestinal uncomfortable side effects with the primary dose, suggesting it could have a extra tolerable long-term profile and enhance affected person adherence.
Worth Motion: AMGN inventory is up 1.58% at $265.33 eventually verify Friday.
Learn Subsequent:
Picture by way of Shutterstock.
Market Information and Information delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
